Bioatla Stock Analysis

BCAB -  USA Stock  

USD 10.07  0.02  0.20%

The big decline in price over the last few months for Bioatla could raise concerns from investors as the firm it trading at a share price of 10.07 on 713,500 in volume. The company management teams failed to add value to investors and positioning the firm supply of money to exploit market volatility in December. However, diversifying your holdings with Bioatla or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.05. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Bioatla partners.
Continue to Trending Equities.

Bioatla Stock Analysis 

 
Refresh
The Bioatla stock analysis report makes it easy to digest most publicly released information about Bioatla and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Bioatla Stock analysis module also helps to analyze the Bioatla price relationship with some important fundamental indicators such as market cap and management efficiency.

Bioatla Stock Analysis Notes

About 17.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.76. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bioatla recorded a loss per share of 2.16. The entity had not issued any dividends in recent years. BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. The company was founded in 2007 and is based in San Diego, California. Bioatla operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 36 people. For more info on Bioatla please contact the company at 858 558 0708 or go to https://www.bioatla.com.

Bioatla Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Bioatla's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Bioatla or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Bioatla generated a negative expected return over the last 90 days
Bioatla has high historical volatility and very poor performance
Bioatla has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 250 K. Net Loss for the year was (79.43 M) with loss before overhead, payroll, taxes, and interest of (19.5 M).
Bioatla currently holds about 269.92 M in cash with (55.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.33.
Bioatla has a frail financial position based on the latest SEC disclosures
Roughly 73.0% of the company shares are held by institutions such as insurance companies
Latest headline from investingnews.com: AMGEN AND BIOLABS LA AT THE LUNDQUIST INSTITUTE ANNOUNCE THAT KARMA BIOTECHNOLOGIES WILL RECEIVE THE SECOND AMGEN GOLDEN TICKET - InvestingNews.com

Bioatla Upcoming and Recent Events

Earnings reports are used by Bioatla to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Bioatla previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report21st of February 2022
Next Earnings Report11th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End21st of February 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Bioatla Largest EPS Surprises

Earnings surprises can significantly impact Bioatla's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-05-12
2021-03-31-0.46-0.56-0.121 
2021-03-24
2020-12-31-0.66-0.8738-0.213832 
2021-11-15
2021-09-30-0.4567-0.697-0.240352 
View All Earnings Estimates

Bioatla SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Bioatla prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Bioatla investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Bioatla specific information freely available to individual and institutional investors to make a timely investment decision.
10th of January 2022
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
View
21st of December 2021
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
19th of November 2021
Termination of a Material Definitive Agreement
View
29th of September 2021
Financial Statements and Exhibits. Unregistered Sales of Equity Securities. Entry into a Material Definitive Agreement
View
3rd of September 2021
Unclassified Corporate Event
View
28th of June 2021
Unclassified Corporate Event
View
16th of June 2021
Submission of Matters to a Vote of Security Holders
View
12th of April 2021
Unclassified Corporate Event
View

Bioatla Thematic Classifications

In addition to having Bioatla stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical Products IdeaPharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French
Pharmaceutical Products IdeaPharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French

Bioatla Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Bioatla is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bioatla backward and forwards among themselves. Bioatla's institutional investor refers to the entity that pools money to purchase Bioatla's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Fmr LlcCommon Shares4.8 M141.4 M
Soleus Capital Management LpCommon Shares2.5 M74.1 M
Wellington Management Group LlpCommon Shares2.3 M67.5 M
Vanguard Group IncCommon Shares2.1 M61.5 M
Cormorant Asset Management LpCommon Shares1.8 M53.5 M
Janus Henderson Group PlcCommon Shares1.7 M50.9 M
Blackrock IncCommon Shares1.3 M37.4 M
Note, although Bioatla's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Bioatla Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 406.67 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bioatla's market, we take the total number of its shares issued and multiply it by Bioatla's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Bioatla Profitablity

Bioatla's profitability indicators refer to fundamental financial ratios that showcase Bioatla's ability to generate income relative to its revenue or operating costs. If, let's say, Bioatla is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Bioatla's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Bioatla's profitability requires more research than a typical breakdown of Bioatla's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(0.32) (0.35) 
Return on Average Equity(0.42) (0.43) 
Return on Invested Capital 2.81  3.03 
Return on Sales(72.30) (74.21) 

Management Efficiency

The entity has return on total asset (ROA) of (32.84) % which means that it has lost $32.84 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (69.36) %, meaning that it created substantial loss on money invested by shareholders. Bioatla management efficiency ratios could be used to measure how well bioatla manages its routine affairs as well as how well it operates its assets and liabilities. The current year Return on Invested Capital is expected to grow to 3.03, whereas Return on Average Assets are forecasted to decline to (0.35) . Bioatla Total Assets are projected to increase significantly based on the last few years of reporting. The past year's Total Assets were at 281.68 Million. The current year Current Assets is expected to grow to about 298.6 M, whereas Return on Average Assets are forecasted to decline to (0.35) .
Last ReportedProjected for 2022
Book Value per Share 28.65  30.91 
Enterprise Value over EBIT(26.10) (28.16) 
Enterprise Value over EBITDA(26.84) (28.96) 
Price to Book Value 4.52  4.49 
Tangible Assets Book Value per Share 33.42  36.06 
Enterprise Value898.1 M892.8 M
Tangible Asset Value281.7 M303.9 M

Technical Drivers

As of the 23rd of January, Bioatla shows the risk adjusted performance of (0.28), and Mean Deviation of 3.04. Bioatla technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze nineteen technical drivers for Bioatla, which can be compared to its rivals. Please confirm Bioatla maximum drawdown, semi variance, and the relationship between the jensen alpha and potential upside to decide if Bioatla is priced correctly, providing market reflects its regular price of 10.07 per share. Given that Bioatla has jensen alpha of (1.34), we suggest you to validate Bioatla's prevailing market performance to make sure the company can sustain itself at a future point.

Bioatla Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Exponential Moving Average is calculated by weighting recent values of Bioatla more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

Bioatla Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bioatla insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bioatla's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bioatla insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Vasquez Christian over two weeks ago via Macroaxis 
Payment of 194 shares by Vasquez Christian of Bioatla subject to Rule 16b-3
Vasquez Christian over a month ago via Macroaxis 
Sale by Vasquez Christian of tradable shares of Bioatla
Vasquez Christian over a month ago via Macroaxis 
Sale by Vasquez Christian of 642 shares of Bioatla
Smith Scott Andrew over a month ago via Macroaxis 
Sale by Smith Scott Andrew of 2925 shares of Bioatla
Vasquez Christian over a month ago via Macroaxis 
Sale by Vasquez Christian of 214 shares of Bioatla
Sievers Eric over a month ago via Macroaxis 
Sale by Sievers Eric of 110 shares of Bioatla
Steinman Lawrence over two months ago via Macroaxis 
Sale by Steinman Lawrence of 450 shares of Bioatla
Sievers Eric over three months ago via Macroaxis 
Sale by Sievers Eric of 592 shares of Bioatla
Levy Guy over three months ago via Macroaxis 
Bioatla exotic insider transaction detected
Steinman Lawrence over three months ago via Macroaxis 
Sale by Steinman Lawrence of 450 shares of Bioatla
Sievers Eric over three months ago via Macroaxis 
Sale by Sievers Eric of 6883 shares of Bioatla
Levy Guy over three months ago via Macroaxis 
Bioatla exotic insider transaction detected

Bioatla Predictive Daily Indicators

Bioatla intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Bioatla stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Bioatla Forecast Models

Bioatla time-series forecasting models is one of many Bioatla's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Bioatla's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Bioatla Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Bioatla stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Bioatla shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Bioatla. By using and applying Bioatla Stock analysis, traders can create a robust methodology for identifying Bioatla entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin(70.19) (72.04) 
Gross Margin 0.90  0.89 
Profit Margin(75.22) (77.19) 
BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. The company was founded in 2007 and is based in San Diego, California. Bioatla operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 36 people.

Current Bioatla Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Bioatla analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Bioatla analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
69.0Strong Buy4Odds
Bioatla current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Bioatla analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Bioatla stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Bioatla, talking to its executives and customers, or listening to Bioatla conference calls.
Bioatla Analyst Advice Details

Bioatla Stock Analysis Indicators

Bioatla stock analysis indicators help investors evaluate how Bioatla stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Bioatla shares will generate the highest return on investment. By understating and applying Bioatla stock analysis, traders can identify Bioatla position entry and exit signals to maximize returns.
Quick Ratio5.97
Fifty Two Week Low11.04
Shares Short Prior Month2.41M
Average Daily Volume Last 10 Day575.97k
Average Daily Volume In Three Month290.73k
Shares Percent Shares Out8.39%
Short Percent Of Float10.94%
Forward Price Earnings-3.56
Float Shares27.18M
Fifty Two Week High76.63
Enterprise Value To Ebitda-4.56
Fifty Day Average22.18
Two Hundred Day Average35.42
Enterprise Value To Revenue1,606.37
Continue to Trending Equities. Note that the Bioatla information on this page should be used as a complementary analysis to other Bioatla's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Watchlist Optimization module to optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm.

Complementary Tools for Bioatla Stock analysis

When running Bioatla price analysis, check to measure Bioatla's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioatla is operating at the current time. Most of Bioatla's value examination focuses on studying past and present price action to predict the probability of Bioatla's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bioatla's price. Additionally, you may evaluate how the addition of Bioatla to your portfolios can decrease your overall portfolio volatility.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Is Bioatla's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bioatla. If investors know Bioatla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bioatla listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bioatla is measured differently than its book value, which is the value of Bioatla that is recorded on the company's balance sheet. Investors also form their own opinion of Bioatla's value that differs from its market value or its book value, called intrinsic value, which is Bioatla's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bioatla's market value can be influenced by many factors that don't directly affect Bioatla's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bioatla's value and its price as these two are different measures arrived at by different means. Investors typically determine Bioatla value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bioatla's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.